Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Применение препарата сорафениб при лечении гепатоцеллюлярной карциномы (Обзор клинических и неинтервенционных исследований: исследование GIDEON)
Применение препарата сорафениб при лечении гепатоцеллюлярной карциномы (Обзор клинических и неинтервенционных исследований: исследование GIDEON)
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus сisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532–38.
2. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835–44.
3. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300.
4. Llovet JM et al. J Clin Oncol. 2007; 25(suppl 18): LBA1. Updated from oral presentation at ASCO; Chicago, IL; June 2007.
5. Abou-Alfa G, Johnson P, Knox J et al. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the 2007 meeting of the European CanCer Organization. Eur J Cancer (Suppl.) 2007; 5: 259.
6. Директива 2001/20/EC Совета парламента Европы (от 4 апреля 2001 г.).
7. Lencioni БR, Marrero J, Venook A et al. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract 2010; 64 (8): 1034–41.
8. Jager DВ, Ma JH, Korbenfeld E et al. PREDICT (Patient Characteristics in Renal Cell Carcinoma and Daily Practice Treatment with Nexavar) Global Noninterventional Study: First Interim results. Presented at ECCO 15 and 34th ESMO Multidisciplinary Congress, Berlin, Germany, 20–24 September.
9. Llovet JM, Ricci S, Mazzaferrro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359; 378–90.
10. NCT00901901. Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH). http: //clinicaltrials.gov/ct2/show/NCT00901901?term=nct00 901901&rank=1 (accessed April 2010)
11. NCT00855218. A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Trans-arterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). http: //clinicaltrials.gov/ct2/show/NCT00855218?term=nct00855218&rank=1 (accessed April 2010).
2. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835–44.
3. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300.
4. Llovet JM et al. J Clin Oncol. 2007; 25(suppl 18): LBA1. Updated from oral presentation at ASCO; Chicago, IL; June 2007.
5. Abou-Alfa G, Johnson P, Knox J et al. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the 2007 meeting of the European CanCer Organization. Eur J Cancer (Suppl.) 2007; 5: 259.
6. Директива 2001/20/EC Совета парламента Европы (от 4 апреля 2001 г.).
7. Lencioni БR, Marrero J, Venook A et al. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int J Clin Pract 2010; 64 (8): 1034–41.
8. Jager DВ, Ma JH, Korbenfeld E et al. PREDICT (Patient Characteristics in Renal Cell Carcinoma and Daily Practice Treatment with Nexavar) Global Noninterventional Study: First Interim results. Presented at ECCO 15 and 34th ESMO Multidisciplinary Congress, Berlin, Germany, 20–24 September.
9. Llovet JM, Ricci S, Mazzaferrro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359; 378–90.
10. NCT00901901. Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH). http: //clinicaltrials.gov/ct2/show/NCT00901901?term=nct00 901901&rank=1 (accessed April 2010)
11. NCT00855218. A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Trans-arterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). http: //clinicaltrials.gov/ct2/show/NCT00855218?term=nct00855218&rank=1 (accessed April 2010).
Авторы
В.А.Горбунова
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.